Acellera

Executive Summary

Acellera is a Barcelona-based startup leveraging artificial intelligence and quantum chemistry to transform early-stage drug discovery. Founded in 2016, the company develops computational platforms that simulate molecular interactions with high accuracy, reducing the time and cost of identifying promising drug candidates. By combining machine learning with physics-based simulations, Acellera aims to address key bottlenecks in preclinical development, including target identification, hit discovery, and lead optimization. The company's technology is particularly suited for complex diseases where traditional screening methods are inefficient, offering a pathway to accelerate the discovery of novel therapeutics. With a focus on the European biotech ecosystem, Acellera is positioned to capitalize on growing demand for AI-driven drug discovery tools. While the company remains private and has not disclosed funding or valuation details, its presence in the AI/ML category suggests potential for significant impact. The next 12-18 months will be critical for Acellera to secure strategic partnerships or raise additional capital to scale its platform. If successful, the company could emerge as a key player in the computational drug discovery space, competing with larger players like Recursion and Schrödinger.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major pharmaceutical company40% success
• Q2 2026Completion of a validation study demonstrating platform accuracy60% success
• Q3 2026Series B funding round of $20M+45% success